2'-Deoxy-5-fluorocytidine (10356-76-0) is a DNA methyltransferase inhibitor currently in clinical trials for breast cancer and other solid tumors¹. Like 5'-Azacytidine (Cat.# 10-1267) and decitabine (Cat.# 10-2412), 2-Deoxy-5-fluorocytidine is a pyrimidine analog that integrates into chromatin to inhibit DNA methylation². It blocks proliferation in colon cancer-derived HCT116 cells by activating DNA response pathways³. It inhibits various strains of pathogenic avian influenza viruses in vitro and in vivo⁴.

References/Citations
1) Ren et al. (2011), DNA hypermethylation as a chemotherapy target; Cell Signal, 23 1082
2) Gowher et al. (2004), Mechanism of inhibition of DNA methyltransferases by cytidine analogs in cancer therapy; Cancer Biol. Ther., 3 1062
3) Zhao et al. (2002), Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway; Springerplus, 1 65
4) Kumaki et al. (2001), In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections; Antiviral Res., 92 329